Tresiba Flextouch Injection

Insulin Degludec
200 Units/ml
Novo Nordisk A/S
Pack size 3ml Pre-filled Pen x 3
Dispensing mode POM
Source DENMARK
AgentCITY MEDICAL STORE
Retail Price 717.00 AED

Indications

Tresiba Flextouch Injection is used for: Diabetes Mellitus

Adult Dose

Adult: S/C: Insulin Degludec is ultra long-acting basal insulin for once-daily at any time of the day, preferably at the same time every day. Initiation: Patients with type 2 diabetes mellitus: The recommended daily starting dose is 10 units followed by individual dosage adjustments. Patients with type 1 diabetes mellitus: One third to one half of the total daily insulin dose; as a general rule, 0.2-0.4 units/kg can be used to calculate the initial total daily insulin dose in insulin-naïve patients with type 1 diabetes Insulin Degludec is to be used once-daily with meal-time insulin and requires subsequent individual dosage adjustments. Starting dose in patients already on insulin therapy Type 1 and type 2 diabetes mellitus: Start insulin degludec at the same unit dose as the total daily long- or intermediate-acting insulin unit dose In patients with type 2 diabetes mellitus, Insulin Degludec can be administered alone or in any combination with oral anti-diabetic medicinal products, GLP-1 receptor agonists and bolus insulin. In type 1 diabetes mellitus, Insulin Degludec must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements. Dose Adjustments Individualize and titrate the dose based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal The recommended days between dose increases is 3-4 days Dose adjustments may be needed with changes in physical activity, changes in meal patterns (ie, macronutrient content or timing of food intake), changes in renal or hepatic function, or during acute illness to minimize the risk of hypoglycemia or hyperglycemia

Child Dose

Safety and efficacy not established

Renal Dose

Administration

Inject SC once daily at any time of day Inject SC into the thigh, upper arm, or abdomen Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy Do not administer IV, IM, or in an insulin infusion pump

Contra Indications

Hypersensitivity to the active substance or to any of the excipients.Hypoglycaemia, Hyperglycaemia, Eye disorder.

Precautions

Insulin Degludecs must not be injected into a vein (intravenously) or a muscle (intramuscularly) and must not be used in infusion pumps. There is no experience with Insulin Degludec in children and adolescents under 18 years of age. Lactation: Unknown if distributed in human breast milk

Pregnancy-Lactation

Pregnancy There are no available data with insulin degludec in pregnant women to inform a drug-associated risk for major birth defects and miscarriage There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy Animal studies The effect of insulin degludec was consistent with those observed with human insulin as both caused preimplantation and postimplantation losses and visceral/skeletal abnormalities in rats at an insulin degludec dose of 21 U/kg/day (~5 times the human exposure [AUC] at a human SC dose of 0.75 U/kg/day) and in rabbits at a dose of 3.3 U/kg/day (~10 times the AUC at a human SC dose of 0.75 U/kg/day) The effects are probably secondary to maternal hypoglycemia Lactation There are no data on the presence of insulin degludec in human milk, the effects on the breastfed infant, or the effects on milk production Insulin degludec is present in rat milk Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

Interactions

Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.

Adverse Effects

Side effects of Insulin Degludec : >10% Nasopharyngitis (12.9-23.9%), Severe hypoglycemic episode (0.3-12.3%), Upper respiratory tract infection (8.4-11.9%), Headache (8.8-11.8%) 1-10% Diarrhea (6.3%), Sinusitis (5.1%), Gastroenteritis (5.1%), Injection site reactions (3.8%), Peripheral edema (0.9-3%) <1% Lipodystrophy

Mechanism of Action

Once-daily basal insulin analogue Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue

Note

Tresiba Flextouch 200 Units/ml Injection manufactured by Novo Nordisk A/S. Its generic name is Insulin Degludec. Tresiba Flextouch is availble in United Arab Emirates. Farmaco UAE drug index information on Tresiba Flextouch Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Insulin Degludec :